Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A
Diabetes Care. 1982 Nov-Dec;5 Suppl 2:43-52. doi: 10.2337/diacare.5.2.s43.
This study describes the pharmacokinetics of three intermediate-acting insulin preparations, NPH porcine insulin, NPH human insulin (recombinant DNA), and "Depot-A" insulin, a mixture of 20% regular and 80% NPH human insulin from Eli Lilly and Company. Metabolic healthy normal weight volunteers were selected for the study. After overnight fasting, each test person received 0.4 U of each insulin per kg body weight injected subcutaneously in the triceps area of the arm. To prevent severe hypoglycemia, the test persons were connected to a "GCIIS Biostator" with blood glucose clamp at the 60 mg/dl level. Peripheral blood was sampled at regular intervals for glucose, insulin, and C-peptide determination. More elevated insulin levels were measured after application of both NPH human insulin and "Depot-A" insulin than after NPH porcine insulin. A more rapid decrease in the blood glucose concentration was observed after injection of both human insulin preparations than after porcine insulin. The dextrose output of the "GCIIS Biostator" was more pronounced in both human insulins than after the porcine preparation. After the injection of NPH human and NPH porcine insulin, significant differences were calculated between the concentrations of these two insulins in the blood, from the 2nd to the 10th hour (P less than 0.05-P less than 0.005) and between the dextrose output of the "GCIIS Biostator" from the 3rd to the 8.5th hour (P less than 0.05). The fall of the C-peptide concentration to the lower detection limit of the assay reflects suppression of the endogenous B-cell secretion and confirms the measure of peripheral insulin concentrations as a result of the exogenously applied insulin. Although all investigations were performed under identical experimental conditions and equal dosages of each insulin were injected, higher insulin concentrations and a stronger biologic effect, shown by larger amount of dextrose delivered, were observed in both human insulins than in porcine insulin. Why this phenomenon occurs is as yet unclear. The clamp technique used with the "GCIIS Biostator" enables establishment of the biologic profile of any insulin, and thus represents a valuable tool in comparative studies.
本研究描述了三种中效胰岛素制剂的药代动力学,即中性精蛋白锌猪胰岛素、中性精蛋白锌人胰岛素(重组DNA)以及“储库-A”胰岛素(礼来公司生产的20%普通胰岛素与80%中性精蛋白锌人胰岛素的混合物)。选取代谢健康的正常体重志愿者进行该研究。在隔夜禁食后,每位测试者在手臂肱三头肌区域皮下注射每千克体重0.4单位的每种胰岛素。为预防严重低血糖,测试者通过血糖钳定连接到“GCIIS生物调节器”,将血糖水平维持在60mg/dl。定期采集外周血以测定血糖、胰岛素和C肽。与中性精蛋白锌猪胰岛素相比,应用中性精蛋白锌人胰岛素和“储库-A”胰岛素后测得的胰岛素水平更高。与猪胰岛素相比,注射两种人胰岛素制剂后观察到血糖浓度下降更快。两种人胰岛素制剂时“GCIIS生物调节器”的葡萄糖输出比猪胰岛素制剂时更明显。注射中性精蛋白锌人胰岛素和中性精蛋白锌猪胰岛素后,在第2至10小时这两种胰岛素在血液中的浓度之间计算出显著差异(P小于0.05 - P小于0.005),并且在第3至8.5小时“GCIIS生物调节器”的葡萄糖输出之间也存在显著差异(P小于0.05)。C肽浓度降至检测下限反映了内源性B细胞分泌受到抑制,并证实了外源性应用胰岛素后外周胰岛素浓度的测定。尽管所有研究均在相同实验条件下进行且每种胰岛素注射剂量相同,但与猪胰岛素相比,两种人胰岛素均观察到更高的胰岛素浓度以及更强的生物学效应(表现为输送的葡萄糖量更大)。这种现象为何发生尚不清楚。与“GCIIS生物调节器”一起使用的钳定技术能够建立任何胰岛素的生物学特征,因此在比较研究中是一种有价值的工具。